Table 1.

Relationship between miR-29c-3p and clinicopathological parameters in 66 patients with LSCC

Clinicopathologic parameters	Value, No.(%)	miR-29c-3p expression ($\overline{X}\pm S$)	P-value
Gender
Male	62 (93.94)	2.61 ± 0.28	0.855
Female	4 (6.06)	2.59 ± 0.30
Age
≤ 60 y	26 (39.39)	2.62 ± 0.30	0.904
> 60 y	40 (60.61)	2.61 ± 0.27
Drinking
Yes	21 (31.82)	2.53 ± 0.30	0.118
No	45 (68.18)	2.64 ± 0.27
Smoking index
< 400	30 (45.45)	2.72 ± 0.25	0.002
≥ 400	36 (54.55)	2.51 ± 0.27
Tumor size
≤ 3 cm	38 (57.58)	2.68 ± 0.25	0.011
> 3 cm	28 (42.42)	2.50 ± 0.29
Tumor site
Supraglottic	19 (28.79)	2.47 ± 0.23	0.010
Glottic	45 (68.18)	2.68 ± 0.28
Subglottic	2 (3.03)	2.39 ± 0.06
Differentiation
Well	36 (54.55)	2.69 ± 0.28	0.029
Moderate	23 (34.85)	2.54 ± 0.25
Poor	7 (10.60)	2.43 ± 0.24
Lymph node metastasis
N0	36 (54.55)	2.71 ± 0.28	0.001
N+	30 (45.45)	2.49 ± 0.24
T classification
T1	7 (10.61)	2.89 ± .0.18	0.001
T2	14 (21.21)	2.74 ± .0.22
T3	13 (19.70)	2.57 ± .0.65
T4	32 (48.48)	2.51 ± 0.27
TNM stage
I	7 (10.61)	2.89 ± 0.18	0.004
II	13 (19.70)	2.72 ± 0.25
III	14 (21.21)	2.57 ± 0.24
IV	32 (48.48)	2.52 ± 0.28

One-way ANOVA was used to analyze the correlation between the expression of miR-29c and clinicopathological parameters of the patients.

*indicates P < 0.05.